title: Zero mortality of continuous veno-venous hemodiafiltration with PMMA hemofilter after pediatric cardiac surgery.
abstract: OBJECTIVE
  Continuous veno-venous hemodiafiltration (CVVH) is used as one of the modalities of continuous renal replacement therapy (CRRT) in pediatric intensive units. The aim of our study was to investigate the use of CVVH in small children with acute renal failure (ARF) after cardiac surgery.
  
  
  METHODS
  Between June 2005 and June 2008, 7 patients who required dialysis after pediatric cardiac surgery without ECMO underwent CVVH with polymethylmethacrylate membrane (PMMA) treatment. The definition of ARF was based on a 100% rise in serum creatinine (Cr) concentration, oliguria. On the other hand, PMMA-CVVH was weaned in patients with satisfactory urine output, stable biochemical markers of renal function and adequate fluid balance.
  
  
  RESULTS
  All patients treated with PMMA-CVVH alone (4 boys, 3 girls) had a median age of 36 months and a median body weight of 11 kg. The averaged established time from cardiac operation to CVVH was 2.6 days. There was a significant decrease in the post-filter compared with pre-filter levels of BUN, Cr, potassium concentration. There were no significant changes in systolic blood pressure, lactate level and CRP; however, it was unnecessary for all patients to use epinephrine.
  
  
  CONCLUSIONS
  Continuous veno-venous hemodiafiltration with PMMA-CVVH without ECMO achieved a surprisingly Zero mortality.
authors: Department of Cardiovascular Surgery, Gunma Children's Medical Center, Shibukawa, Gunma, Japan. yonomiyataka@msn.com
authors: Takashi
authors: T
authors: Miyamoto
authors: Akihiro
authors: A
authors: Yoshimoto
authors: Kazuhito
authors: K
authors: Tatsu
authors: Kentaro
authors: K
authors: Ikeda
authors: Yoichiro
authors: Y
authors: Ishii
authors: Tomio
authors: T
authors: Kobayashi
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D004867:Equipment Design; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery*; D017583:Hemodiafiltration / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D006801:Humans; D007223:Infant; D007564:Japan; D008297:Male; D008567:Membranes, Artificial; D019904:Polymethyl Methacrylate; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008567:Membranes, Artificial; D019904:Polymethyl Methacrylate